The cancer biopsy market is estimated to be valued at US$ 25.61 Bn in 2023 and is expected to exhibit a CAGR of 14.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


The cancer biopsy market involves products and services used for the diagnosis of cancer through the removal of samples of suspicious cells or tissues from organs like breast, lung, prostate and others. Some key products in this market include needles, instruments, assays and services. Biopsy helps in determining the location and stage of cancer, which helps physicians in deciding the appropriate course of treatment.

Market Dynamics:
The global cancer biopsy market is mainly driven by the increasing prevalence of cancer cases globally. As per the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Rising awareness about early detection and growing geriatric population, who are more prone to developing cancer, further propels the market growth. In addition, the approval and launch of innovative biopsy products is also fueling the market growth. For instance, in 2021, QIAGEN launched therascreen PIK3CA RGQ PCR Kit, which is used to detect PIK3CA gene mutations in formalin-fixed, paraffin-embedded (FFPE) tissue samples from breast and colon cancer patients. The kit helps physicians in deciding treatment options for cancer patients.

However, the high cost of diagnostic procedures and lack of reimbursement policies in developing nations act as a major restraint for the cancer biopsy market. Whereas, untapped opportunities in emerging markets are likely to offer lucrative growth opportunities over the forecast period.

SWOT Analysis

Strength: Cancer biopsy procedures provide a minimally invasive technique to diagnose cancer accurately. Advancements in biopsy devices allow precise targeted sampling of suspicious areas. Growing demand for minimally invasive surgeries increases the usage of biopsy tools.

Weakness: Biopsy procedures require skilled professionals to operate complex tools and analyze samples. Shortage of pathologists can limit the diagnostic procedures. Certain risky biopsy methods cause complications in some patients.

Opportunity: Emerging economies offer high growth opportunities due to increasing healthcare investments. New liquid biopsy tests provide non-invasive cancer detection from blood samples. Personalized cancer treatments boost the usage of genomic profiling tools.

Threats: Strict regulations for approval of biopsy devices increases the development costs. Reimbursement issues in some countries pose challenges. Alternative cancer screening methods threaten the biopsy market.


Key Takeaways

The Global Cancer Biopsy Market Growth is expected to witness high growth, exhibiting CAGR of 14.% over the forecast period, due to increasing prevalence of cancer worldwide. Rising awareness about early diagnosis and personalized treatment will propel the demand for biopsy tools.

Regional analysis

North America dominates the cancer biopsy market with the highest revenue share. Early adoption of advanced diagnostic technologies in the region accelerates the market growth. Asia Pacific is projected to grow at the fastest pace during the forecast period due to rising healthcare spending and increasing government initiatives for cancer screening in developing countries.

Key players

Key players operating in the cancer biopsy market are QIAGEN, Illumina, Inc., Angle PLC, Myriad Genetics, COUNSYL, Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, F. Hoffmann-La Roche Ltd., Epigenomics AG, BD (Becton, Dickinson and Company), and Helio Health (Laboratory for Advanced Medicine), among others.

Get More Insights On This Topic: http://igniteblog01.weebly.com/blog/the-cancer-biopsy-market-is-estimated-to-witness-high-growth-owing-to-advancement-in-biopsy-devices